-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 11, 2021, Cheng Cheng Zhang's team from Texas Southwestern Medical Center published an article on Nature Cancer LILRB3 supports acute myeloid leukemia development and regulates T-cell antitumor immune responses through the TRAF2-cFLIP-NF-κB signaling axis, studied the role of LILRB3, a member of the LILRB family, in the development of acute myeloid leukemia (AML)
.
First, the researchers identified a new signal transduction mechanism through which the inhibitory receptor LILRB3 activates NFkB, which mediates leukemia cell survival and T cell suppression
.
This solves a paradox-why inhibitory receptors that should inhibit cell activation can also induce cell activation under certain circumstances
.
Second, the researchers worked with the team of Dr.
An Zhiqiang from the University of Houston to develop an anti-LILRB3 blocking antibody
.
Experiments have shown that blocking LILRB3 signaling with an antagonist antibody will hinder the progression of AML
.
This study is parallel to Cheng Cheng Zhang's team's study of the role of the LILRB family in the tumor microenvironment of solid cancers.
In addition, researchers have also conducted extensive preclinical studies
.
Original link: https://doi.
org/10.
1038/s43018-021-00262-0 Platemaker: Notes for reprinting on the 11th [Non-original article] The copyright of this article belongs to the author of the article.
Personal forwarding and sharing are welcome.
Reprinting without permission is prohibited.
The author has all legal rights, and offenders must be investigated
.
.
First, the researchers identified a new signal transduction mechanism through which the inhibitory receptor LILRB3 activates NFkB, which mediates leukemia cell survival and T cell suppression
.
This solves a paradox-why inhibitory receptors that should inhibit cell activation can also induce cell activation under certain circumstances
.
Second, the researchers worked with the team of Dr.
An Zhiqiang from the University of Houston to develop an anti-LILRB3 blocking antibody
.
Experiments have shown that blocking LILRB3 signaling with an antagonist antibody will hinder the progression of AML
.
This study is parallel to Cheng Cheng Zhang's team's study of the role of the LILRB family in the tumor microenvironment of solid cancers.
In addition, researchers have also conducted extensive preclinical studies
.
Original link: https://doi.
org/10.
1038/s43018-021-00262-0 Platemaker: Notes for reprinting on the 11th [Non-original article] The copyright of this article belongs to the author of the article.
Personal forwarding and sharing are welcome.
Reprinting without permission is prohibited.
The author has all legal rights, and offenders must be investigated
.
